CME Credits: 0.25
NASH and type 2 diabetes: A podcast mini-series
In this podcast series, we look into the importance of considering the potential presence of NASH during type 2 diabetes management
Professor of Hepatology, University of Birmingham, United Kingdom
Professor Newsome runs the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which includes a large multi-disciplinary clinic for patients with NAFLD. He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapies in NAFLD published in the Lancet and the NEJM. He is the Co-ordinating Investigator for several global NAFLD studies. He chaired the national guidelines for liver transplantation in NAFLD and sat on the NICE Guideline Development Group for NAFLD. He led the recent UK multi-stakeholder guideline group on the management of abnormal liver blood tests and led on NAFLD for the recent EASL Lancet Liver Commission. He recently completed his term as Secretary General (President) of EASL.
In this podcast series, we look into the importance of considering the potential presence of NASH during type 2 diabetes management